Veru Inc (VERU)

$0.78

Market is closed - opens 7 PM, 24 Jun 2024

Insights on Veru Inc

  • Decreasing Revenue

    Revenue is down for the last 3 quarters, 3.86M → 2.14M (in $), with an average decrease of 22.3% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 3 quarters, -23.76M → -8.27M (in $), with an average increase of 93.6% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 77.4% return, outperforming this stock by 110.7%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 245.6% return, outperforming this stock by 336.4%

Performance

  • $0.75
    $0.79
    $0.78
    downward going graph

    3.71%

    Downside

    Day's Volatility :5.09%

    Upside

    1.44%

    downward going graph
  • $0.36
    $1.92
    $0.78
    downward going graph

    53.85%

    Downside

    52 Weeks Volatility :81.25%

    Upside

    59.38%

    downward going graph

Returns

PeriodVeru IncSector (Consumer Staples)Index (Russel 2000)
3 Months
39.43%
2.7%
0.0%
6 Months
9.97%
9.1%
0.0%
1 Year
-33.26%
4.6%
0.0%
3 Years
-90.82%
12.2%
-23.0%

Highlights

Market Capitalization
114.3M
Book Value
$0.31
Earnings Per Share (EPS)
-0.35
PEG Ratio
0.0
Wall Street Target Price
3.44
Profit Margin
-289.01%
Operating Margin TTM
-239.13%
Return On Assets TTM
-40.76%
Return On Equity TTM
-125.82%
Revenue TTM
13.5M
Revenue Per Share TTM
0.13
Quarterly Revenue Growth YOY
-37.2%
Gross Profit TTM
30.6M
EBITDA
-46.0M
Diluted Eps TTM
-0.35
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.27
EPS Estimate Next Year
-0.3
EPS Estimate Current Quarter
-0.05
EPS Estimate Next Quarter
-0.06

Analyst Recommendation

Buy
    88%Buy
    11%Hold
    0
    0%Sell
Based on 9 Wall street analysts offering stock ratings for Veru Inc(by analysts ranked 0 to 5 stars)
Based on 9 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
8
8
7
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 341.03%

Current $0.78
Target $3.44

Company Financials

FY18Y/Y Change
Revenue
15.9M
↑ 16.18%
Net Income
-23.9M
↑ 262.04%
Net Profit Margin
-150.89%
↓ 102.47%
FY19Y/Y Change
Revenue
31.8M
↑ 100.47%
Net Income
-12.0M
↓ 49.8%
Net Profit Margin
-37.79%
↑ 113.1%
FY20Y/Y Change
Revenue
42.6M
↑ 33.92%
Net Income
-19.0M
↑ 57.88%
Net Profit Margin
-44.55%
↓ 6.76%
FY21Y/Y Change
Revenue
61.3M
↑ 43.83%
Net Income
7.4M
↓ 138.97%
Net Profit Margin
12.07%
↑ 56.62%
FY22Y/Y Change
Revenue
39.4M
↓ 35.76%
Net Income
-83.8M
↓ 1232.97%
Net Profit Margin
-212.88%
↓ 224.95%
FY23Y/Y Change
Revenue
16.3M
↓ 58.59%
Net Income
-93.1M
↑ 11.12%
Net Profit Margin
-571.2%
↓ 358.32%
Q4 FY22Q/Q Change
Revenue
2.5M
↓ 3.12%
Net Income
-36.8M
↓ 10.19%
Net Profit Margin
-1.5K%
↑ 115.61%
Q1 FY23Q/Q Change
Revenue
6.6M
↑ 162.62%
Net Income
-38.8M
↑ 5.29%
Net Profit Margin
-589.02%
↑ 880.09%
Q2 FY23Q/Q Change
Revenue
3.3M
↓ 49.27%
Net Income
6.3M
↓ 116.28%
Net Profit Margin
188.98%
↑ 778.0%
Q3 FY23Q/Q Change
Revenue
3.9M
↑ 15.59%
Net Income
-23.8M
↓ 476.42%
Net Profit Margin
-615.43%
↓ 804.41%
Q4 FY23Q/Q Change
Revenue
2.1M
↓ 44.57%
Net Income
-8.3M
↓ 65.18%
Net Profit Margin
-386.6%
↑ 228.83%
Q1 FY24Q/Q Change
Revenue
2.1M
↑ 0.0%
Net Income
-8.3M
↑ 0.0%
Net Profit Margin
-386.6%
↑ 0.0%
FY18Y/Y Change
Total Assets
48.5M
↓ 12.39%
Total Liabilities
19.0M
↑ 176.82%
FY19Y/Y Change
Total Assets
53.6M
↑ 10.68%
Total Liabilities
21.3M
↑ 12.25%
FY20Y/Y Change
Total Assets
51.5M
↓ 3.89%
Total Liabilities
21.4M
↑ 0.64%
FY21Y/Y Change
Total Assets
178.1M
↑ 245.62%
Total Liabilities
25.9M
↑ 20.62%
FY22Y/Y Change
Total Assets
136.1M
↓ 23.59%
Total Liabilities
55.3M
↑ 113.85%
FY23Y/Y Change
Total Assets
50.6M
↓ 62.83%
Total Liabilities
32.8M
↓ 40.65%
Q4 FY22Q/Q Change
Total Assets
103.8M
↓ 23.76%
Total Liabilities
54.7M
↓ 1.09%
Q1 FY23Q/Q Change
Total Assets
70.3M
↓ 32.31%
Total Liabilities
53.5M
↓ 2.1%
Q2 FY23Q/Q Change
Total Assets
75.2M
↑ 7.03%
Total Liabilities
40.8M
↓ 23.78%
Q3 FY23Q/Q Change
Total Assets
50.6M
↓ 32.71%
Total Liabilities
32.8M
↓ 19.59%
Q4 FY23Q/Q Change
Total Assets
80.6M
↑ 59.24%
Total Liabilities
29.0M
↓ 11.73%
Q1 FY24Q/Q Change
Total Assets
80.6M
↑ 0.0%
Total Liabilities
29.0M
↑ 0.0%
FY18Y/Y Change
Operating Cash Flow
-11.5M
↓ 1274.72%
Investing Cash Flow
-50.7K
↓ 43.95%
Financing Cash Flow
12.1M
↑ 0.0%
FY19Y/Y Change
Operating Cash Flow
-5.5M
↓ 52.49%
Investing Cash Flow
-108.5K
↑ 114.23%
Financing Cash Flow
8.1M
↓ 32.7%
FY20Y/Y Change
Operating Cash Flow
-1.9M
↓ 64.81%
Investing Cash Flow
-105.8K
↓ 2.54%
Financing Cash Flow
9.3M
↑ 14.76%
FY21Y/Y Change
Operating Cash Flow
-15.6M
↑ 706.75%
Investing Cash Flow
14.6M
↓ 13926.92%
Financing Cash Flow
109.7M
↑ 1076.04%
FY22Y/Y Change
Operating Cash Flow
-47.5M
↑ 205.09%
Investing Cash Flow
4.3M
↓ 70.82%
Financing Cash Flow
1.1M
↓ 99.03%
Q4 FY22Q/Q Change
Operating Cash Flow
-34.5M
↑ 65.4%
Investing Cash Flow
-285.6K
↑ 91.9%
Financing Cash Flow
1.6M
↑ 133.17%
Q1 FY23Q/Q Change
Operating Cash Flow
-25.6M
↓ 26.0%
Investing Cash Flow
-141.6K
↓ 50.42%
Financing Cash Flow
2.3M
↑ 45.78%
Q2 FY23Q/Q Change
Operating Cash Flow
-18.4M
↓ 27.88%
Investing Cash Flow
6.0M
↓ 4319.54%
Financing Cash Flow
5.2M
↑ 128.0%

Technicals Summary

Sell

Neutral

Buy

Veru Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Veru Inc
Veru Inc
-43.01%
9.97%
-33.26%
-90.82%
-63.34%
Moderna, Inc.
Moderna, Inc.
-18.32%
40.58%
10.72%
-39.74%
850.14%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
7.05%
24.38%
35.05%
97.21%
236.95%
Novo Nordisk A/s
Novo Nordisk A/s
5.92%
38.21%
77.43%
245.57%
453.56%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
4.73%
15.66%
34.62%
148.17%
158.93%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Veru Inc
Veru Inc
NA
NA
0.0
-0.27
-1.26
-0.41
NA
0.31
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-6.7
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
30.93
30.93
1.46
44.13
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
49.78
49.78
2.36
3.47
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
30.61
30.61
0.53
17.09
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Veru Inc
Veru Inc
Buy
$114.3M
-63.34%
NA
-289.01%
Moderna, Inc.
Moderna, Inc.
Buy
$51.5B
850.14%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$115.3B
236.95%
30.93
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$644.0B
453.56%
49.78
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$121.7B
158.93%
30.61
39.46%

Institutional Holdings

  • Adage Capital Partners Gp LLC

    7.53%
  • Perceptive Advisors LLC

    3.82%
  • Vanguard Group Inc

    3.22%
  • Rosalind Advisors, Inc.

    3.07%
  • Octagon Capital Advisors LP

    2.60%
  • Morgan Stanley - Brokerage Accounts

    1.87%

Company Information

the female health company/veru healthcare is a therapeutics company focused on developing and commercializing pharmaceuticals and devices in men’s and women’s health and oncology. to realize this goal, veru healthcare has three divisions: pharmaceutical and devices, consumer health products, and public sector. for men, product and product candidates are in the areas of benign prostatic hyperplasia, male infertility, amelioration of side effects of hormonal prostate cancer therapies, prostate cancer, gout, and sexual dysfunction. women’s health has product candidates for female sexual health and advanced breast and ovarian cancers and markets fc2, a disposable contraceptive device, to ob gyn physicians and is the only female condom approved by fda that offers dual protection against sexually transmitted infections, including hiv/aids and the zika virus, and unintended pregnancy. since the female health company began distributing fc2 in 2007, the product has been shipped to 144 countries

Organization
Veru Inc
Employees
189
CEO
Dr. Mitchell S. Steiner F.A.C.S., M.D.
Industry
Consumer Non-Durables

FAQs